维普期刊资源整合服务平台（V6.5）

32篇 您的检索式：作者名="Sledge G W"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Angiogenesis and antiangiogenic therapy显示文摘	Miller K D	2002	Curr ProblCaacer2002，26，1：	1
2	Cispla- tin as frst-line therapy for metastatic breast cancer 显示文摘	SLEDGE G W Jr LOEHRER P J St ROTH B J	1988	J Clin Oncol1988，6，12：	1
3	Redefining the target:chemotherapeutics as antiangiogenics显示文摘	Miller K D Sweeney C J Sledge G W Jr	2001	J Clin Oncol2001，19，4：	1
4	Making personalized cancer medicine a reality:challenges and op- portunities in the development of biomarkers and companion diagnostics 显示文摘	Parkinson D R Johnson B E Sledge G W	2012	Clinical Cancer Research2012，18，3：	1
5	A phase Ⅰ/ Ⅱ dose - escalation trial of bevaeizumab in previously treated metastatic breast cancer 显示文摘	COBLEIGH M A LANGMUIR V K SLEDGE G W	2003	Semin Oncol2003，30，16：	1
6	Association of polymorphisms of angiogenesis genes with breast cancer显示文摘	Schneider B P Radovich M Sledge G W	2008	Breast Cancer Res Treat2008，111，1：	1
7	Cisplatin as firstline therapy for metastatic breast cancer 显示文摘	Sledge G W Jr Loehrer P J Sr Roth B J	1988	J Clin Oncol1988，6，12：	1
8	Redefining the target:chemotherapeutics as antiangi0genics显示文摘	Miller K D Sweeney C J Sledge G W	2001	J Clin Oncol2001，19，4：	1
9	Doxorybincin/pacltaxel combination chemotherapy for metastatic breast cancer: the Easten cooperative Oncolgy Group experience显示文摘	Sledge G W Jr	2003	Sermin Oncol2003，22，3：	1
10	Redefining the target: chemotherapeutics as antiangiogenies 显示文摘	MILLER K D SWEENEY C J SLEDGE G W	2001	J Clin Oncol2001，19，4：	1
11	Effects of doxycycline on human prostase cancer cells in vitro显示文摘	Fife R S Sledge G W Roth B	1998	Cancer Lett1998，127，12：	1
12	Redefi-ning the target: chemotherapeutics as antiangiogenics显示文摘	MILLER K D SWEENEY C J SLEDGE G W J R	2001	J Clin Oncol2001，19，4：	1
13	Redefining the target: chemotherapeutics as antiangiogenics显示文摘	Miller K D Sweeney C J Sledge G W Jr	2001	J Clin Oncol2001，19，：	1
14	Phase Ⅲ trail of doxorubiein, paelitaxel, and the combination of doxorubiein and paclitaxel as front - line chemotherapy for metastatic breast cancer:an intergroup trail (E1193)显示文摘	Sledge G W Neuberg D Bemardo P	2003	J Clin Oncol2003，21，：	1
15	The role of chemotherapy for metastatic breast cancer显示文摘	Miller K D Sledge G W Jr	1999	Hematol Oncol Clin North Am1999，13，2：	1
16	Phase Ⅲ trial or doxorubicin,paclitaxel,and the combination on doxorubicin and paclitaxel as front- line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)显示文摘	Sledge G W Neuberg D Bermardo P	2003	J Clin Oncol2003，21，4：	1
17	Redefining the target:chemotherapeutics as antiangiogenic显示文摘	Miller K D Sweeney C J Sledge G W	2001	Clin Oncol2001，19，5：	1
18	Cisplantin as first-line therapy for metastatic breast cancer显示文摘	Sledge G W Jr Loehrer P J Sr Roth B J	1988	J Clin Oncol1988，6，：	1
19	Redefining the target: chemotherapeutics as antiangiogenics 显示文摘	Miller K D Sweeney C J Sledge G W Jr	2001	J Clin Oncol2001，19，4：	1
20	Phase HI trial of doxorubicin, paclitaxel, and the combinalion of doxorubicin and pa- elitaxel as front - line ehemotheraphy for metastatic breast cancer : an intergroup trial(Ell93) 显示文摘	SLEDGE G W NEUBERG D BERNARDO P	2003	J Clin Oncol2003，21，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示